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Abstract
Background: Circulating cell free DNA in serum as well as serum-autoantibodies and the serum proteome have
great potential to contribute to early cancer diagnostics via non invasive blood tests. However, most DNA
preparation protocols destroy the protein fraction and therefore do not allow subsequent protein analyses. In this
study a novel approach based on methyl binding domain protein (MBD) is described to overcome the technical
difficulties of combining DNA and protein analysis out of one single serum sample.
Methods: Serum or plasma samples from 98 control individuals and 54 breast cancer patients were evaluated
upon silica membrane- or MBD affinity-based DNA isolation via qPCR targeting potential DNA methylation markers
as well as by protein-microarrays for tumor-autoantibody testing.
Results: In control individuals, an average DNA level of 22.8 ± 25.7 ng/ml was detected applying the silica
membrane based protocol and 8.5 ± 7.5 ng/ml using the MBD-approach, both values strongly dependent on the
serum sample preparation methods used. In contrast to malignant and benign tumor serum samples, cell free DNA
concentrations were significantly elevated in sera of metastasizing breast cancer patients. Technical evaluation
revealed that serum upon MBD-based DNA isolation is suitable for protein-array analyses when data are consistent
to untreated serum samples.
Conclusion: MBD affinity purification allows DNA isolations under native conditions retaining the protein function,
thus for example enabling combined analyses of DNA methylation and autoantigene-profiles from the same serum
sample and thereby improving minimal invasive diagnostics.
Background
The prognostic potential of cell free nucleic acids in
plasma and serum caused a lot of attention in current
efforts to improve diagnoses of several cancerous dis-
eases [1,2]. During the last years various approaches in
this field, like the determination of genetic aberrations,
the methylation status of the DNA [3], DNA level [4]
and DNA-integrity [5] as well as miscellaneous proteo-
mic approaches [6] have been reported to have clinical
relevance. Despite this, breast cancer diagnosis still relies
on physical examinations and mammography, because
no accurate and reliable approach is currently available
to be implemented into an effective diagnostic test.
Therefore, the need for a simple non invasive blood test
to perform routine pre-symptomatic screenings that
improve early diagnosis is high.
Serum markers for breast cancer detection may be
divided into two areas. On the one hand tumor-induced
DNA aberrations detectable in serum of cancer patients
which has been already examined in clinical trials [7].
On the other hand, there is the field of tumor-specific
changes in proteins where serum-protein analyses [8]
and the novel approach of tumor-autoantibody signa-
tures [9,10] are applied for diagnostics. A combined ana-
lysis of cell free serum DNA and for example serum-
autoantibodies should have the potential to increase the
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reliability and diagnostic power of non-invasive blood
tests.
Due to the different demands on sample preparation
and the very often limited sample material, a combined
analysis of DNA and proteins for biomarker identifica-
tion remains difficult. The currently often used silica
membrane-based DNA isolation strategy does not allow
subsequent protein analyses, because it relies mostly on
protein-denaturation and includes standard ProteinaseK
treatment of the samples [11,12].
To overcome these constraints, we developed a DNA
isolation protocol based on the usage of a recombinantly
expressed methyl binding protein (MBD) to extract
genomic DNA from serum or plasma samples, thereby
keeping the proteome intact.
MBD is the methyl CpG binding domain of the
MeCP2 protein, which binds symmetrically methylated
CpGs in any sequence context, and is involved in med-
iating methylation dependent transcriptional repression
[13,14]. Although there is a strong evidence that MeCP2
binds exclusively methylated DNA fragments in vivo, a
DNA methylation-independent binding activity of
MeCP2 in vitro was also described in concordant litera-
ture [15,16], which makes it suitable for general in vitro
DNA analysis.
Up to now, recombinant MBD protein, which is avail-
able upon overexpression of the cloned His-tagged pro-
tein in E.coli [17], has been predominantly used for
DNA methylation analyses. The MBD protein has been
preferably applied being immobilized in an affinity chro-
matography like manner with NaCl gradient elution
steps to isolate methylated DNA for PCR and gel ana-
lyses [18], as well as for methylome profiling via Geno-
mic Sequencing [19].
Alternative applications comprised DNA isolation
from stool, where for example Zou H. et al applied a
MBD column to minimize the background E. coli DNA
[20], or direct binding of MBD to immobilized methy-
lated DNA [21]. Beside these exclusively affinity based
MBD applications, an assay was developed, where MBD
was combined with methylation-sensitive restriction
enzymes (COMPARE-MS) to minimize false positives
for methylation assessment [22].
The workflow presented here uses MBD protein
attached to Ni-Sepharose beads for affinity based-DNA
purification that enables the simultaneous analyses of
cell free serum DNA and serum proteins, resulting in a
time and sample saving procedure. MBD isolated serum
DNA has been found particularly suitable for DNA
methylation analyses, and has allowed us to confirm an
elevated level of cell free serum DNA of breast cancer
patients with a malignant metastasizing neoplasm [23].
Autoantibody signatures of the protein fraction of MBD
processed serum samples of control individuals were
comparable to signatures derived from unprocessed
serum of these individuals, indicating the suitability of
MBD processed serum samples for immunological ana-
lyses upon DNA isolation.
Methods
Serum and plasma sample preparation
Serum and plasma samples were obtained from three
different sources. Numbers of samples as well as type of
processing are also given in Table 1. Serum samples
from the Austrian Institute of Technology (source 1),
age and sex matched, mean age of 27, taken from
healthy volunteers, were prepared as follows: incubation
of blood in Vacuette 9 ml Z Serum Clot Activator
(Greiner Bio One, Frickenhausen, Germany) for 30 min
followed by centrifugation at 1,800 × g for 10 min at
room temperature. Serum-aliquots of 2 ml were stored
at -80°C. The blood plasma was taken from the same
donors as the serum at a single withdrawal. For the iso-
lation of plasma, the blood samples were taken with a
BD Vacutainer (BD diagnostics) glass whole blood tube
with K3EDTA, centrifuged at 1300 × g for 10 min at 4°
C and stored in 500 μl aliquots at -80°C (source 1).
Serum samples provided by the Austrian Red Cross
Blood Center (source 2) were treated according to the
protocol described above. These serum samples were
arranged into three sex matched subgroups: group 1
(36-45 years old), group 2 (46-55 years old), group 3
(56-65 years old). These samples were qualified as blood
donors according the eligibility criteria of the Austrian
Red Cross and are denoted as control individuals.
Samples obtained from the General Hospital in
Vienna (AKH) consisting of control individuals, breast
cancer patients and patients with metastasizing breast
cancer were centrifuged at 1000 × g for 15 min and
stored in 200 μl aliquots at -80°C until usage (source 3).
The non-cancer patients of the AKH were defined upon
personal interviews and examinations to exclude any
familial history of breast cancer, any papable breast-
nodules and any history or presence of cancerous
disease.
Both the Red Cross Blood Center and the AKH pro-
vided anonymized samples after completion of all testing
procedures and according to the institute’s guidelines.
The study was approved by the ethics committee of the
Medical University Vienna and was carried out in com-
pliance with the Helsinki Declaration.
Protein expression and MBD-bead assembly
The E. coli strain BL21, containing the pET6HMBD
plasmid, kindly provided by Sally H. Cross [24], was
grown in Luria-Bertani medium with 30 μg/ml chloram-
phenicol and 50 μg/ml ampicillin. LB medium (10 ml)
was inoculated with glycerol stock of E.coli strain BL21.
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Bacteria were grown for 8 h at 37°C and then further
cultured over night in 250 ml LB medium. Culture was
then split into three main cultures of 750 ml LB med-
ium each for further culturing. The main cultures were
grown in 2 l flasks for approximately 8 h, until an opti-
cal density (600 nm) of 0.6 was reached. Then recombi-
nant protein expression was induced by adding
Isopropyl-ß-D-thiogalactopyranosid (IPTG) to a final
concentration of 0.4 mM. After incubation at 37°C over
night, the E. coli biomass was collected by centrifugation
at 4,000 rpm for 20 min. The E. coli biomass (approxi-
mately 3 g/l LB medium) was washed twice with PBS
and resuspended in lyses buffer (20 mM HEPES, 1 M
NaCl, 2 M Urea, 10% glycerol, 0.5 mM EDTA, 0.1% Tri-
tonX, pH = 8) to reach a concentration of 0.3 g biomass
per ml. Samples were stored at -20°C until usage.
For MBD protein purification E.coli cells (800 μl) were
mixed with 500 μl lyses buffer and lysed by repeated
bead whirling mixing for 30 s in Lyses Matrix A tubes
(MP Biomedicals, Eschwege, Germany) on a FastPrep24
instrument (MP Biomedicals). The bacterial extract was
then centrifuged at 13,000 rpm for 10 min and the
supernatant transferred to a new vial. Centrifugation at
13,000 rpm for 10 min was repeated until all cell debris
was spun down.
A volume of 200 μl of a 50% suspension of Ni-Sephar-
ose beads (Adar Biotech, Rehovot, Israel) were washed
in 500 μl water, followed by centrifugation for 1 min at
1000 × g and removal of the supernatant from the
beads. The beads were then equilibrated by adding 500
μl buffer A (20 mM HEPES, 100 mM NaCl, 10% gly-
cerol, 20 mM beta-Mercaptoethanol (added fresh daily),
0.5 mM PMSF, 0.1 mM TritonX, pH = 8) and centri-
fuged at 1000 × g for 1 min. This procedure was
repeated twice and then the beads were resuspended in
100 μl buffer A. His-tagged MBD-protein was bound to
the equilibrated beads by addition of 800 μl bacterial
extract (derived from approximately 250 mg E.coli wet
cell weight) and 500 μl 2 × buffer A, and incubated for
two hours on ice at which the beads were held in sus-
pension upon repeated mixing.
MBD-loaded beads (200 μl) were washed twice by
adding 500 μl wash buffer (buffer A, plus 10 mM Imida-
zol) followed by centrifugation at 1,000 × g for 1 min.
The MBD protein was either eluted from beads with
buffer A plus 500 mM Imidazol or used for DNA isola-
tion. Protein concentration was measured with a BioRad
Dc-Protein assay (Bio-Rad laboratories). Protein purifi-
cation was visualized on a SDS page gel (NuPage Novex
Bis-Tris Gel, Invitrogen, Lofer, Austria) by applying ali-
quots of 6.5 μl from each purification step and a dilu-
tion of 1 μl crude lysat in 10 μl loading-volume onto
the gel. Proteins were mixed with 2.5 μl loading dye
(Bio-Rad laboratories) and 1.5 μl Reducing agent
(BioRad laboratories), denatured via 10 minutes at 70°C
and loaded onto the gel, where 200 V were applied for
35 minutes.
MBD loaded bead preparation for DNA purification
was performed as follows: Residual E.coli DNA was
removed with buffer B (1.5 M NaCl, 20 mM HEPES, 20
mM b-Mercaptoethanol, 0.5 mM PMSF, 0.1 mM Tri-
tonX, pH = 8). The beads (100 μl) were then resus-
pended in 100 μl buffer A.
MBD-loaded bead-based DNA Isolation
For DNA extraction using the MBD immobilized Ni-
beads, 1 ml of serum was diluted with 1 ml of 2 × buffer
A and incubated with an aliquot of 60 μl of prepared
50% MBD loaded bead suspension in buffer A for 2 h
on a thermo mixer (Eppendorf, Hamburg, Germany) at
450 rpm at room temperature. After centrifugation at
1000 × g for 1 min beads were separated and used for
Table 1 Overview of sample processing
Parameter source 1 source 2 source 3
Origin AIT Austrian Red Cross AKH
Sample type serum/plasma serum serum
Test persons control individuals
age and sex matched
control individuals
age and sex matched
control/breast cancer
Quantity serum, n = 12
plasma, n = 8
serum, n = 48 non-canc., n = 30
cancer met., n = 12
cancer mal., n = 30
cancer ben., n = 12
Isolation MBD/silica* MBD/silica* MBD/silica**
Analyses DNA quantification
multiplexed PCR test
qPCR measurments
array based autoanitbody
tests
DNA quantification
multiplexed PCR test
DNA quantification
AIT, Austrian Institute of Technology; AKH, Vienna General Hospital; cancer met., serum samples from cancer patients with a metastasizing tumor; cancer mal.,
patients with an malign tumor; cancer ben., derived from patient with a benign tumor; *DNA of all samples isolated by both isolation methods; ** DNA from 72
samples of this group was isolated using “silica”, 12 using “MBD” MBD, methyl-binding domain protein; silica, silica membrane-based isolation
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DNA isolation. The supernatant was used for autoanti-
body-profiling (see below).
The MBD-loaded beads including the bound serum
DNA were washed twice with buffer C (20 mM Hepes,
100 mM NaCl, 10% glycerol, pH = 8) and resuspended
in 145 μl 10 mM Tris-Cl buffer, pH = 8. DNA was
eluted from MBD loaded beads by ProteinaseK-digestion
(20 mg/ml, Fermentas, St.Leon-Rot, Austria). The reac-
tion contained 5 μl ProteinaseK in a volume of 150 μl
and was incubated at 55°C for 20 min followed by an
incubation at 65°C for 20 min. DNA was then isolated
from the ProteinaseK reaction supernatant using Quia-
gen MinElute columns (Quiagen, Venlo, Netherlands).
Purification was performed according to manufacturers
instruction with an elution volume of 17 μl.
Silica membrane-based DNA Isolation
DNA isolation from serum using common silica mem-
brane-based isolation strategy was performed applying
the Roche High pure template preparation kit (Roche
Diagnostics, Mannheim, Germany). The protocol was
adapted according to Müller HM. et al. [25]. Isolation
was performed according to the manufacturer’s instruc-
tion except the following protocol steps: the 800 μl of
serum samples were split into 2 aliquots of 400 μl and
each mixed with 400 μl of Roche Binding Buffer and 80
μl ProteinaseK (20 mg/μl Fermentas, St.Leon-Rot, Aus-
tria). After 15 min of incubation at 55°C, 200 μl isopro-
panol was added to each aliquot. Aliquots were mixed
and an aliquot of 540 μl per serum sample were subse-
quently loaded four times to the column followed by a
centrifugation step of 1 min at 8,000 × g. The flow
through after each centrifugation was transferred back
onto the same column and centrifuged again. Inhibitor-
removal and washing steps were performed according to
manufacturers’ protocol, but the DNA was eluted in 55
μl of elution buffer.
DNA quantification
DNA concentration was measured with the “Quant it”
Pico Green kit (Invitrogen, Lofer, Austria) according to
the manufacturers’ protocol with a reduced reaction
volume of 100 μl. Samples and standards were excited
at 480 nm and emission was read at 520 nm using a
BioRad IQ5 Real time PCR detection system. A five-
point lambda DNA standard concentration curve ran-
ging from 15 pg/μl to 250 pg/μl was measured in a
volume of 100 μl.
Microarray-based autoantibody tests
cDNA clones (fetal brain expression library) found
reactive with serum from control individuals and
breast cancer patients were used for protein expres-
sion and microarray generation (data not shown).
Protein chips were processed as described by Stempfer
R. et al. [26].
Serum samples, all originating from source 1, were
either diluted 1 to 10 for untreated serum or 1 to 5 for
samples after MBD-DNA isolation with PBST contain-
ing 3% nonfat dried bovine milk. Slides were blocked
with DIGeasy Hyb (Roche Diagnostics, Mannheim, Ger-
many) for 30 min, followed by two 5 min washing steps
with PBST. A volume of 150 μl of diluted serum was
applied onto each array and incubated for 2 h at room
temperature. Slides were washed twice with PBST and
detection of serum auto-antibodies was performed by
incubation with Cy3 conjugated Affini Pure rabbit anti
human IgA + IgG + IgM (Jackson Immuno Research) in
a dilution of 1:25000 in PBST plus 3% nonfat dried
bovine milk for 2 h followed by a 5 min washing step in
PBST. Slides were scanned on a Gene Pix 4000a scanner
(Axon Instruments) with a resolution of 10 μm at a
photomultiplier tube setting of 700 PMT. Images were
analyzed using Gene Pix software. Raw data were
imported to GraphPad Prism (GraphPad Software, Inc.)
to create Pearson correlation plots and to determine
average signal intensities.
DNA amplification and qPCR tests
DNA recovery of distinct isolation methods was con-
trolled by two Multiplex-PCRs, which were performed
with 6 primer pairs per reaction targeting the 5’-UTRs
of CpG methylation controlled genes (primer sequences
on request). An aliquot of 2 μl per serum DNA isolate
served as template for the reaction and the (2-step)-PCR
reaction setup and cycling was performed as published
previously [27]. PCR products (10 μl) were loaded onto
a 2% agarose gel containing 0.5 μg/ml ethidiumbromide.
qPCR analyses were carried out to assess the DNA
integrity and enrichment of methylated DNA. All qPCR
reactions were performed in a 384 well format on a
Roche Light cycler 480 in reaction volumes of 10 μl
containing 0.125 μM of each Primer, 0.3 U Hotstart Taq
(Qiagen), 5% DMSO containing SYBR green to reach a
dilution of 0.5 × in the final reaction and 166 μM
dNTP-mix. A volume of 2 μl of Silica-membrane based
DNA isolates served as template, whereas 1 μl template
was used for the qPCR reaction of serum or plasma iso-
lates, processed with MBD loaded beads. The PCR pro-
gram was identical to the multiplex PCR program with
the exception that for qPCR analyses 50 cycles were per-
formed. Accuracy of Ct-values was assured via melting
curve analyses of every analyzed reaction.
Statistical tests
Mean and standard derivations were calculated for each
data set. Pearson correlation coefficients were applied
as a measurement of similarity between the data sets.
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A Wilcoxon rang sum test was applied for the not nor-
mally distributed data set of elevated DNA levels. None
of the discussed data sets were normalized.
Results
Silica and MBD isolated DNA amount in serum/plasma of
control individuals
To evaluate the new MBD loaded bead-based serum
DNA isolation strategy 152 serum or plasma samples
were processed with either a common silica-based DNA
isolation workflow or with MBD loaded beads. Charac-
terization of the serum DNA isolates showed concor-
dant properties with respect to DNA recovery and
relative amounts between patient groups, of both the
MBD- and the optimized silica membrane- based DNA
purification protocol.
The mean DNA amount, isolated from 1 ml serum of
60 control individuals using the silica membrane based
approach was 22.8 ± 25.7 ng/ml (mean ± SD.), ranging
from 0.3 ng - 39.1 ng. By MBD-based isolation from 1
ml serum of 36 control individuals an average of 8.51 ±
7.3 ng/ml of DNA could be obtained, ranging from 0.7
ng - 25.4 ng. Extracted DNA amounts per ml serum
(measured with Pico Green) varied dependent on the
serum source, but showed similar trends when compar-
ing both isolation strategies (Figure 1).
DNA extraction of plasma samples (source 1) was per-
formed in triplicate in three independent experiments. A
plasma DNA concentration of 1.8 ± 1.6 ng/ml (mean ±
SD) was measured per ml plasma for the MBD protocol
and 5.8 ± 5.1 ng/ml for the membrane based protocol
(Figure 1). Comparing plasma DNA levels to DNA
amounts isolated from 1 ml serum, we could ascertain
that plasma DNA isolations of control individuals pro-
vide 57% (P = 0.002, Student t-test) of the DNA amount
detected in serum of the same blood donors.
Selective DNA binding of MBD loaded beads: The
MBD-isolated DNA yields were on average 25% (P <
0.001, Student t-test) of the DNA amounts obtained
with the silica membrane based protocol. This reduced
DNA amounts were observed in serum samples from
sources 1-3 and in plasma samples from source 1 (Fig-
ure 1). However, this reduced DNA amounts isolated
with MBD loaded beads did not affect the serum DNA
recovery, because the agarose gel image based analyses
of amplifiable serum DNA fragments was not influenced
by the methylation status of DNA fragments.
To further elucidate the reason for the reduced DNA
amount, which might be due to the selective binding
character of the MBD protein for methylated DNA,
qPCRs were performed on serum isolates targeting both
known methylated and unmethylated gene regions. We
made the observation that unmethylated DNA regions
provided later Ct values when compared to silica mem-
brane based isolation strategy but methylated DNA
regions showed the same Ct values compared to DNA
isolated with silica membrane (Additional File 1) These
data indicated that the methylated DNA fraction is
strongly enriched by the application of the MBD loaded
bead extraction procedure. We concluded from this
observation that the MBD DNA isolation procedure per-
forms equal to silica membrane based DNA isolation
strategies when methylated DNA is analyzed.
DNA amounts in serum of patients with breast cancer
To get an impression whether data, produced with the
MBD serum processing workflow, are comparable to
published findings in current literature and our own
experimental observation achieved with silica membrane
based isolation strategy, DNA extractions with both
strategies were performed on sera of breast cancer
patients (Figure 2). The sera of six breast cancer patients
with metastasizing disease and six control individuals
were processed with MBD loaded beads. This was based
on concentration measurement of serum DNA of 24
normal controls, 36 malign breast cancer patients,
whereat 6 patients had a metastasizing disease, and 12
patients with a benign breast cancer applying a silica
membrane based protocol (Table 1). The DNA amount
in sera of malignant breast cancer patient without
metastases was found to be at 13.7 ± 12.7 ng/ml. For
patients with a benign disease we measured 12.6 ± 11.4
ng/ml. Both groups showed no significant difference
compared to the control individuals which showed a
concentration of 12.2 ± 7.9 ng/ml per ml serum (mean
Figure 1 Extraction of cell free DNA from control individuals.
Box plot of DNA amount isolated from 1 ml serum or plasma from
(1) Austrian Institute of Technology (n = 12), (2) Austrian Red Cross
(n = 24) and (3) AKH (n = 24). Serum DNA levels were dependent
on serum source. Using the silica-based extraction protocol, mean
amounts of DNA could be isolated ranging from (1), 11.9 ± 10.9 ng/
ml (mean ± SD) and (3), 12.2 ± 9.7 ng/ml to (2), 39.7 ± 32.8 ng/ml.
By contrast using the MBD-based protocol, serum DNA
concentrations of (1) 2.5 ± 1.9 ng/ml, (2) 11.5 ± 7.3 ng/ml and (3)
2.4 ± 1 ng/ml were observed.
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± SD.). Including the measured serum DNA amounts of
patients with metastasizing disease to the malign cancer
group we observed a mean DNA concentration of 20.5
± 21.4, which is an increase compared to non-cancer
patients, but due to variation of the data not significant.
Assessment of quality from cell free serum DNA
To investigate the quality of DNA samples derived from
the two isolation approaches we performed two inde-
pendent multiplex-PCRs with six primers each, based on
the hypothesis that the amplification success for differ-
ent isolates might reflect the DNA quality. As described
in Figure 3A, successful reactions with 12 amplified
fragments were prevailing. Therefore, the isolated DNA
was in general sufficient to perform two six-plex PCR,
which demonstrated a good DNA quality. Amplification
failure rate correlated with low isolated DNA amount, at
which DNA levels below 1 ng per ml showed unsuccess-
ful PCR reactions.
Although amplifying GC-rich templates, PCR products
with a length from 125 bp up to 520 bp were amplified
with high efficiencies in serum and in plasma samples
(Figure 3B). Overall these observations show that
although significantly smaller DNA amounts are isolated
with the MBD based approach the method is still suita-
ble to detect pathological changes in the patients like
the increase of the DNA amount and the approach
yields enough DNA to perform PCR reaction on the iso-
lated methylated and unmethylated DNA fraction and
subsequent gel image analyses with a comparable per-
formance to the silica membrane based approach.
Autoantibody tests of MBD processed serum
To elucidate the effect of MBD based DNA isolation on
the serum protein fraction, we compared auto-antibody
signatures of native serum samples and samples after
MBD-DNA isolation. Using an in house fabricated pro-
tein array comprising 642 different proteins [26], MBD
treated serum/plasma and untreated serum/plasma from
six males and females in duplicate were analyzed con-
cerning their autoantibody profile. Array data showed a
Pearson correlation form 0.67 to 0.86 for the compari-
son of MBD treated serum/plasma and untreated
serum/plasma, whereof two representative samples were
plotted in Figure 4. The log 2 value of the median array
signal intensities of all analyzed MBD processed serum
samples was 11.2 ranging from 9.7 to 12.9 in compari-
son to 10.8 for untreated serum or plasma (range 10.2
to 12.9), excluding an experimental bias introduced by
the MBD loaded bead DNA isolation process. Also
patient gender or blood treatment (serum/plasma) did
Figure 2 Increased level of cell free DNA in serum of Breast
cancer patients with metastasizing disease. Amount of cell free
DNA isolated from 1 ml serum of breast cancer patients with
metastasizing tumors and control individuals obtained from AKH
(source 3). An increased serum DNA amount was detected in sera
from metastasizing tumors with both isolation strategies. (A), silica
based isolation protocol (P = 0.0043, Wilcoxon test); (B) MBD loaded
bead based purification (P = 0.0021, Wilcoxon test).
Figure 3 Qualitiy of cell free serum DNA. (A) reflects the amplification success for each sample using MBD or silica membrane based serum
DNA. A maximum of 12 fragments per sample was possible and in sum 34 samples per isolation approach were analyzed. (B) shows the
amplification success of each fragment getting amplified across all analyzed samples. Both plots (A, B) are based on the analysis of two multiplex
PCRs performed on serum or plasma DNA isolates (source 1, 2).
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not affect median signal intensities significantly. These
data suggest that MBD isolation has a minor effect on
the autoantibody pattern of different sera and plasma
samples, but rather retains protein function. Correlation
plots (Figure 4) furthermore indicate same patterns of
autoantibodies for serum and plasma samples.
Discussion
In serum or plasma of healthy adults as well as breast
cancer patients the amount of cell free DNA [28] is low,
but of great interest for minimal invasive diagnostics
[29]. We developed a serum processing workflow, which
enables to perform DNA studies followed by autoanti-
body tests out of the same serum sample. This addresses
the problem of limited access to clinical sample mate-
rial, which is a constraint of many researchers and clini-
cians [30].
In this present study we could show that it is possible
to isolate serum DNA, suitable for PCR analyses and
especially methylation analyses of cell free DNA, using a
sample processing based on the affinity of MBD to
methylated DNA [16]. Furthermore, the gentle sample
treatment in the DNA isolation step holds the possibility
of additional proteomic analyses and miRNA isolations
or autoantibody tests (the latest we performed in this
work here). We present a new application of the MBD
protein using an advanced bead based approach to iso-
late DNA from serum and plasma samples thereby
retaining protein function. For this we developed a sim-
plified protein purification procedure (Additional File 2).
The expectation of small DNA amounts in serum was
encountered by our strategy to replace the standard salt
elution by a ProteinaseK digestion of the MBD protein
to regain the entire MBD bound DNA. This allowed us
to isolate 2.4 ng/ml DNA out of serum of control indivi-
duals and 6.6 ng/ml of metastasizing breast cancer
patients. However, DNA amounts detected with a mem-
brane based isolation procedure were on average about
three times higher due to the relative low affinity of the
MBD to unmethylated DNA (Additional File 1).
This attribute of the MBD protein derived from
MeCP2 to bind predominantly methylated DNA, is
due to its actual biological function as transcriptional
regulator [31,32]. At qPCR based methylation studies it
turned out, that there is a certain amount of unmethy-
lated DNA bound by the MBD protein even at salt
concentrations above 0.6 M usually recommended for
elution of methylated DNA from the protein (data not
shown). Although there was a significant enrichment
of methylated CpG-rich fragments in the DNA fraction
after MBD-treatment, we propose to include an addi-
tional methyl-sensitive restriction digestion or sodium
bisulfite treatment to guarantee accurate methylation
studies based on the MBD protein, which is also sug-
gested by other researchers in concordant literature
[16,22].
In this study we further investigated if the MBD
loaded bead workflow is suitable for plasma DNA isola-
tions. This approach enabled us to highlight another
topic, namely the direct comparison of DNA levels in
plasma and serum, upon paralleled preparation of
plasma and serum samples out of a single blood with-
drawal. We found 5.8 ± 5.2 ng/ml of cell free DNA in
plasma of control individuals versus 11.9 ± 10.9 ng/ml
prevailing in 1 ml serum of the same patients. The same
ratio of DNA amounts was observed using the MBD
loaded bead isolation protocol. There are reports that
higher DNA levels in serum are due to the clotting pro-
cess and the associated release of DNA from destroyed
white blood cells [3,33] and therefore do not contribute
to alterations of cell-free DNA, tested in different diag-
nostic assays [34]. The fact of additional normal DNA
derived from blood lymphocytes detected in serum may
also be responsible for sample source dependant varying
DNA amounts observed in our study.
Another indication for the universal applicability of
the MBD DNA isolation protocol was the affirmation
of the widely discussed increase of cell free serum
DNA levels in breast cancer patients [35,36] with both
purification approaches, although this elevated DNA
amounts could be observed in few patient sera with a
non-metastasis malign neoplasm and not in sera of
benign tumors. Therefore our data might rather agree
with observations of metastasis cancerous diseases [37]
than with an increase of cell free DNA of overall
malignant cancers [11].
Figure 4 Autoantibody tests of MBD processed serum. Pearson
correlation plots upon X-values of autoantibody protein micro
arrays analyzing serum and plasma samples with and without MBD
treatment. All samples originate from source 1 (AIT). Comparison of
plasma and serum samples were performed on samples obtained
from one single blood withdrawal. The cor-value states the
Pearson’s correlation.
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Because autoantibody-based serum analyses is of high
interest for minimal invasive diagnostics, and research
efforts are on the way for elucidation of antigenic bio-
markers, paralleled analysis of the protein fraction in
addition to DNA based methods are of high relevance
for efficient usage of limiting amounts of retrospective
clinical samples. Serum-autoantibody tests hold the
potential to recognize array bound peptides differentially
dependent on whether these antibodies were produced
in sera of control individuals or patients with a cancer-
ous disease. These peptide sequences may serve as use-
ful biomarkers and soon could support clinical
diagnoses [38,39].
Conclusions
In this study we performed first tests with this new bead
based serum processing workflow, where we primarily
used the DNA-binding characteristics of the MBD pro-
tein to isolate DNA from sera and plasma of control
individuals and breast cancer patients. Hence the MBD
based DNA isolation holds the potential to combine
DNA methylation studies with the detection of any
serum protein marker applicable for clinical diagnoses.
Thus this procedure offers efficient usage of the limiting
amounts of clinical samples for combined testing of
DNA and proteins. This combination of DNA based
diagnostic tests and the analysis of the erum/plasma
protein fraction should be an important step towards
non-invasive cancer tests, because of the increased sta-
tistical power gained by two independent methods. This
would enhance diagnostic reliability and accuracy.
Additional material
Additional file 1: Differential methylated DNA fragments. Ct-values
of differential methylated DNA fragments: DNA was isolated from serum
(source 1, n = 8) either using the silica membrane based approach or
the MBD approach. Four different 5’-UTR regions with known
methylation status in healthy peripheral blood were tested, SALL3, ESR1,
CHFR (all unmethylated loci) and ZNF502 (biallelic methylated loci). A
mean difference between Ct-values regarding the three unmethylated
genes of 2.2 was observed; highlighting the reduced amounts of
unmethylated DNA, isolated by MBD loaded bead approach. For the
ZNF502 gene locus, which is methylated in healthy adults, no significant
difference between Ct-values of two isolation approaches was detected.
Additional file 2: SDS gel of MBD purification. The Coomassie stained
SDS gel outlines our simplified MBD purification protocol and enabled us
to control correct MBD-bead assembly. Aliquots of the several
purification steps were loaded onto the gel. Lane 1, 5 kDa Page Ruler;
Lane 2, crude lysate (1:5 dilution); Lane 3, supernatant of the binding
reaction; Lane 4 and 5, subsequent washing steps with buffer A
containing 10 mM imidazol; Lane 6, purified MBD protein eluted from Ni-
NTA beads, where one band at 11 kDa remained.
Acknowledgements
This work was in part funded by the OeNB Jubiläumsfonds, grant number
P12551, and the project RESOLVE funded by the European Commission
under FP7-HEALTH-F4-2008, Contract no. 202047 http://resolve.punkt-
international.eu/.
We are grateful to Silvia Schönthaler and Rudolf Pichler for their technical
assistance.
Author details
1Molecular Medicine, Austrian Institute of Technology, Muthgasse 11, 1190
Vienna, Austria. 2Department of Obstetrics and Gynecology, Medical
University of Vienna, Währinger Grütel 18 - 20, 1090 Vienna, Austria. 3Blood
Donation Center for Vienna, Lower Austria and Burgenland, Austrian Red
Cross, Wiedner Hauptstraße 32, 1040 Vienna, Austria.
Authors’ contributions
MW carried out PCR, qPCR, purifications and data analyses and drafted the
manuscript. WP performed the gel image analyses. JP participated statistical
analyses and plotted the data. MH participated at the expression of the
protein in E.coli. CFR collected the information about breast cancer patients.
CS collected a patient cohort participated in the collection of clinical data
and contributed to the manuscript. CJ collected a patient cohort and
contributed to the manuscript. CN participated in design and coordination
of the study. AW conceived the study and participated in its design and
contributed to manuscript. All authors read and approved the final paper.
Competing interests
The authors declare that they have no competing interests.
Received: 5 April 2011 Accepted: 6 September 2011
Published: 6 September 2011
References
1. Lo YM, Chiu RW: Next-generation sequencing of plasma/serum DNA: an
emerging research and molecular diagnostic tool. Clin Chem 2009,
55:607-608.
2. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W,
Chyczewski L, Kulikowski M: Circulating free DNA, p53 antibody and
mutations of KRAS gene in endometrial cancer. Int J Cancer 2009.
3. Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer–a
survey. Biochim Biophys Acta 2007, 1775:181-232.
4. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour
DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis
Rev 1999, 18:65-73.
5. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R,
Sokoll LJ, Chan DW, Shih I: Increased plasma DNA integrity in cancer
patients. Cancer Res 2003, 63:3966-3968.
6. Elrick MM, Walgren JL, Mitchell MD, Thompson DC: Proteomics: recent
applications and new technologies. Basic Clin Pharmacol Toxicol 2006,
98:432-441.
7. Anker P, Mulcahy H, Stroun M: Circulating nucleic acids in plasma and
serum as a noninvasive investigation for cancer: time for large-scale
clinical studies? Int J Cancer 2003, 103:149-152.
8. Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ,
Feliberti EC, Perry RR, Drake RR: Serum proteomic biomarker discovery
reflective of stage and obesity in breast cancer patients. J Am Coll Surg
2009, 208:970-978.
9. Kijanka G, Murphy D: Protein arrays as tools for serum autoantibody
marker discovery in cancer. J Proteomics 2009, 72:936-944.
10. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D:
p53 autoantibodies as potential detection and prognostic biomarkers in
serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:859-868.
11. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT: Cell-free DNA:
measurement in various carcinomas and establishment of normal
reference range. Clin Chim Acta 2002, 321:77-87.
12. Seefeld M, El TS, Fan AX, Hahn S, Holzgreve W, Zhong XY: Parallel
assessment of circulatory cell-free DNA by PCR and nucleosomes by
ELISA in breast tumors. Int J Biol Markers 2008, 23:69-73.
13. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, Bird A:
Purification, sequence, and cellular localization of a novel chromosomal
protein that binds to methylated DNA. Cell 1992, 69:905-914.
14. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N,
Strouboulis J, Wolffe AP: Methylated DNA and MeCP2 recruit histone
deacetylase to repress transcription. Nat Genet 1998, 19:187-191.
Wielscher et al. BMC Clinical Pathology 2011, 11:11
http://www.biomedcentral.com/1472-6890/11/11
Page 8 of 9
15. Weitzel JM, Buhrmester H, Stratling WH: Chicken MAR-binding protein
ARBP is homologous to rat methyl-CpG-binding protein MeCP2. Mol Cell
Biol 1997, 17:5656-5666.
16. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, Bird AP:
DNA binding selectivity of MeCP2 due to a requirement for A/T
sequences adjacent to methyl-CpG. Mol Cell 2005, 19:667-678.
17. Cross SH, Charlton JA, Nan X, Bird AP: Purification of CpG islands using a
methylated DNA binding column. Nat Genet 1994, 6:236-244.
18. Shiraishi M, Chuu YH, Sekiya T: Isolation of DNA fragments associated
with methylated CpG islands in human adenocarcinomas of the lung
using a methylated DNA binding column and denaturing gradient gel
electrophoresis. Proc Natl Acad Sci USA 1999, 96:2913-2918.
19. Serre D, Lee BH, Ting AH: MBD-isolated Genome Sequencing provides a
high-throughput and comprehensive survey of DNA methylation in the
human genome. Nucleic Acids Res 2010, 38:391-399.
20. Zou H, Harrington J, Rego RL, Ahlquist DA: A novel method to capture
methylated human DNA from stool: implications for colorectal cancer
screening. Clin Chem 2007, 53:1646-1651.
21. Yu Y, Blair S, Gillespie D, Jensen R, Myszka D, Badran AH, Ghosh I,
Chagovetz A: Direct DNA methylation profiling using methyl binding
domain proteins. Anal Chem 2010, 82:5012-5019.
22. Yegnasubramanian S, Lin X, Haffner MC, DeMarzo AM, Nelson WG:
Combination of methylated-DNA precipitation and methylation-sensitive
restriction enzymes (COMPARE-MS) for the rapid, sensitive and
quantitative detection of DNA methylation. Nucleic Acids Res 2006, 34:e19.
23. Zanetti-Dallenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W,
Zhong XY: Positive correlation of cell-free DNA in plasma/serum in
patients with malignant and benign breast disease. Anticancer Res 2008,
28:921-925.
24. Cross SH, Charlton JA, Nan X, Bird AP: Purification of CpG islands using a
methylated DNA binding column. Nat Genet 1994, 6:236-244.
25. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E,
Marth C, Widschwendter M: DNA methylation in serum of breast cancer
patients: an independent prognostic marker. Cancer Res 2003,
63:7641-7645.
26. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of Gene
Expression Data Using BRB-Array Tools. Cancer Inform 2007, 3:11-17.
27. Weinhaeusel A, Thiele S, Hofner M, Hiort O, Noehammer C: PCR-based
analysis of differentially methylated regions of GNAS enables convenient
diagnostic testing of pseudohypoparathyroidism type Ib. Clin Chem 2008,
54:1537-1545.
28. Zhong XY, Hahn S, Kiefer V, Holzgreve W: Is the quantity of circulatory
cell-free DNA in human plasma and serum samples associated with
gender, age and frequency of blood donations? Ann Hematol 2007,
86:139-143.
29. Gahan PB, Swaminathan R: Circulating nucleic acids in plasma and serum.
Recent developments. Ann N Y Acad Sci 2008, 1137:1-6.
30. Nygaard V, Hovig E: Options available for profiling small samples: a
review of sample amplification technology when combined with
microarray profiling. Nucleic Acids Res 2006, 34:996-1014.
31. Ho KL, McNae IW, Schmiedeberg L, Klose RJ, Bird AP, Walkinshaw MD:
MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol Cell
2008, 29:525-531.
32. Jang JS, Lee SJ, Choi JE, Cha SI, Lee EB, Park TI, Kim CH, Lee WK, Kam S,
Choi JY, Kang YM, Park RW, Kim IS, Cho YL, Jung TH, Han SB, Park JY:
Methyl-CpG binding domain 1 gene polymorphisms and risk of primary
lung cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:2474-2480.
33. Holdenrieder S, Stieber P, Chan LY, Geiger S, Kremer A, Nagel D, Lo YM:
Cell-free DNA in serum and plasma: comparison of ELISA and
quantitative PCR. Clin Chem 2005, 51:1544-1546.
34. Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, Pelosi G,
Goldstraw P, Sozzi G, Pastorino U: Detecting lung cancer in plasma with
the use of multiple genetic markers. Int J Cancer 2004, 108:91-96.
35. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Burki N,
Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free
nuclear and mitochondrial DNA as potential biomarkers for breast
tumors. Mol Cancer 2009, 8:105.
36. Van dA, Elst HJ, Van Laere SJ, Maes H, Huget P, van DP, Van Marck EA,
Vermeulen PB, Dirix LY: The presence of circulating total DNA and
methylated genes is associated with circulating tumour cells in blood
from breast cancer patients. Br J Cancer 2009, 100:1277-1286.
37. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S,
Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M: Circulating
cell-free DNA as a predictive marker for distant metastasis of hepatitis C
virus-related hepatocellular carcinoma. Br J Cancer 2007, 97:1399-1403.
38. Ionov Y: A high throughput method for identifying personalized tumor-
associated antigens. Oncotarget 2010, 1:148-155.
39. Ludwig N, Keller A, Comtesse N, Rheinheimer S, Pallasch C, Fischer U,
Fassbender K, Steudel WI, Lenhof HP, Meese E: Pattern of serum
autoantibodies allows accurate distinction between a tumor and
pathologies of the same organ. Clin Cancer Res 2008, 14:4767-4774.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6890/11/11/prepub
doi:10.1186/1472-6890-11-11
Cite this article as: Wielscher et al.: Methyl-binding domain protein-
based DNA isolation from human blood serum combines DNA analyses
and serum-autoantibody testing. BMC Clinical Pathology 2011 11:11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wielscher et al. BMC Clinical Pathology 2011, 11:11
http://www.biomedcentral.com/1472-6890/11/11
Page 9 of 9
